Notable Labs Ltd
NASDAQ:NTBL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
NTBL's latest stock split occurred on Oct 17, 2023
The company executed a 1-for-35 stock split, meaning that for every 35 shares held, investors received 1 new share.
Before the split, NTBL traded at 0.156 per share. Afterward, the share price was about 4.45.
The adjusted shares began trading on Oct 17, 2023. This was the only stock split in NTBL's history.
Global
Stock Splits Monitor
| Date | Company | Split | Pre-Split Price | Post-Split Price | |
|---|---|---|---|---|---|
|
Apr 21, 2026
|
W
|
WellCell Holdings Co Ltd
HKEX:2477
|
4-for-1
x4
|
111.28 27.82 HKD | 5.06 5.06 HKD |
|
Apr 21, 2026
|
|
Canon Electronics Inc
TSE:7739
|
1-for-6235122
/6235122
|
3635 3635 JPY | N/A |
|
Apr 20, 2026
|
|
AnaptysBio Inc
NASDAQ:ANAB
|
15-for-10
x1.5
|
67.5101 45.0067 USD | 50.95 50.95 USD |
|
Apr 20, 2026
|
|
ConnectM Technology Solutions Inc
NASDAQ:CNTM
|
1-for-32
/32
|
0.265 8.48 USD | 8.48 8.48 USD |
|
Apr 20, 2026
|
|
Eshallgo Inc
NASDAQ:EHGO
|
1-for-16
/16
|
0.1421 2.2736 USD | 2.5 2.5 USD |
7739
ANAB
CNTM
EHGO
Notable Labs Ltd
Glance View
Notable Labs Ltd is a IL-based company operating in Biotechnology industry. Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company committed to developing next-generation, targeted medicines for difficult-to-treat medical conditions. The firm has created a pipeline of therapeutics that address cancer and immune-inflammatory diseases with the goal of significantly improving patient outcomes and overcoming the limitations of approved treatments. The firm's product candidates are built off of two platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications.
